Format

Send to

Choose Destination
Contemp Clin Trials. 2011 Sep;32(5):614-9. doi: 10.1016/j.cct.2011.05.003. Epub 2011 May 17.

Oversight and management of a cell therapy clinical trial network: experience and lessons learned.

Author information

1
University of Texas School of Public Health, Houston, TX 77030, United States. Lemmoye@msn.com

Abstract

The Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the National Heart, Lung, and Blood Institute (NHLBI), was established to develop, coordinate, and conduct multiple collaborative protocols testing the effects of cell therapy on cardiovascular diseases. The Network was born into a difficult political and ethical climate created by the recent removal of a dozen drugs from the US formulary and the temporary halting of 27 gene therapy trials due to safety concerns. This article describes the Network's challenges as it initiated three protocols in a polarized cultural atmosphere at a time when oversight bodies were positioning themselves for the tightest vigilance of promising new therapies. Effective strategies involving ongoing education, open communication, and relationship building with the oversight community are discussed.

PMID:
21616173
PMCID:
PMC3157886
DOI:
10.1016/j.cct.2011.05.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center